BBP

BBP is a passive biotech ETF built to hold U.S.-listed biotechnology companies that have crossed a key milestone: at least one FDA-approved therapy already on the market.

It tracks the LifeSci Biotechnology Products Index, which uses an index committee to screen for “pure” biotech and exclude adjacent categories (like large pharma, medical devices, tools, and vaccines).

The portfolio is equal-weighted and reconstituted twice per year, keeping exposure spread across constituents rather than dominated by mega-caps.